ProQR Therapeutics (NASDAQ:PRQR) Stock Rating Lowered by StockNews.com

ProQR Therapeutics (NASDAQ:PRQR – Get Rating) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

Several other brokerages have also recently commented on PRQR. Raymond James raised their target price on ProQR Therapeutics from $2.00 to $5.00 and gave the stock an “outperform” rating in a research report on Friday, December 23rd. Cantor Fitzgerald upgraded ProQR Therapeutics from a “neutral” rating to an “overweight” rating and set a $5.00 price objective for the company in a research note on Thursday, December 22nd. One analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $3.90.

ProQR Therapeutics Stock Up 7.8 %

Shares of PRQR stock opened at $3.16 on Wednesday. The stock has a market cap of $225.28 million, a P/E ratio of -2.93 and a beta of 0.12. ProQR Therapeutics has a one year low of $0.53 and a one year high of $3.78. The stock has a fifty day moving average price of $3.04 and a 200 day moving average price of $1.87. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.86 and a quick ratio of 3.86.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Opaleye Management Inc. increased its stake in shares of ProQR Therapeutics by 13.0% in the second quarter. Opaleye Management Inc. now owns 2,740,000 shares of the biopharmaceutical company’s stock valued at $2,131,000 after buying an additional 315,000 shares in the last quarter. Vanguard Personalized Indexing Management LLC acquired a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $79,000. Bank of Montreal Can acquired a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $381,000. Two Sigma Advisers LP increased its stake in shares of ProQR Therapeutics by 210.0% in the third quarter. Two Sigma Advisers LP now owns 173,300 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 117,400 shares in the last quarter. Finally, Raymond James & Associates acquired a new stake in shares of ProQR Therapeutics in the third quarter valued at $38,000. 29.79% of the stock is currently owned by institutional investors and hedge funds.

About ProQR Therapeutics

(Get Rating)

ProQR Therapeutics NV is a clinical stage biopharmaceutical company. It is engaged in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases, such as Leber congenital amaurosis 10, Usher syndrome type 2, and autosomal dominant retinitis pigmentosa.